DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo

DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo

Objectives: Dipeptidyl peptidase 4 (DPP-4) inhibition is a new therapeutic strategy for type 2 diabetic patients. DPP-4 has been reported to enhance inflammation. However, the effect of DPP-4 inhibition on inflammation remains unknown. Lipopolysaccharide (LPS) is a strong inducer of inflammation and...

Full description

Bibliographic Details
Main Authors: Masahiko Ishida, Wei-Ren Shen, Keisuke Kimura, Akiko Kishikawa, Kazuhiro Shima, Saika Ogawa, Jiawei Qi, Fumitoshi Ohori, Takahiro Noguchi, Aseel Marahleh, Hideki Kitaura
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Osteoclast
DPP-4 inhibitor
LPS
Diabetes
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332218322042

Internet

http://www.sciencedirect.com/science/article/pii/S0753332218322042

Similar Items